Psoriasis and comorbid diseases: Epidemiology

Journal of the American Academy of Dermatology

Volumn 76, Issue 3, 2017, Pages 377-390

  Takeshita, Junko ^a   Grewal, Sungat ^a   Langan, Sinéad M ^b   Mehta, Nehal N ^c   Ogdie, Alexis ^a   Van Voorhees, Abby S ^d   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

cardiovascular disease; chronic kidney disease; comorbidities; Crohn's disease; depression; infection; lymphoma; metabolic syndrome; nonalcoholic fatty liver disease; psoriasis; psoriatic arthritis

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CUTANEOUS T CELL LYMPHOMA; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; INFECTION; INFLAMMATORY BOWEL DISEASE; KIDNEY DISEASE; LIVER DISEASE; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; OBESITY; PEPTIC ULCER; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDERED BREATHING; STREPTOCOCCAL PHARYNGITIS; SYSTEMATIC REVIEW (TOPIC); CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; MOOD DISORDERS; NEOPLASMS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; MOOD DISORDERS; NEOPLASMS; OBESITY; PREVALENCE; PSORIASIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85013168223     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2016.07.064     Document Type: Review

References (159)

1. 1 National Psoraisis Foundation. Available from: URL: https://www.psoriasis.org/cure_known_statistics. Accessed October 1, 2015.
2. 2 Kurd, S.K., Gelfand, J.M., The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 60 (2009), 218–224.
3. 3 Rachakonda, T.D., Schupp, C.W., Armstrong, A.W., Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70 (2014), 512–516.
4. 4 Rapp, S.R., Feldman, S.R., Exum, M.L., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41:3 pt 1 (1999), 401–407.
5. 5 Strauss, H., Zur Lehre von der neurogenen und der thyreogenen Glykosurie. Dtsch Med Wochenschr 20 (1897), 309–312.
6. 6 Reed, W.B., Becker, S.W., Rohde, R., et al. Psoriasis and arthritis. Clinicopathologic study. Arch Dermatol 83 (1961), 541–548.
7. 7 McDonald, C.J., Calabresi, P., Psoriasis and occlusive vascular disease. Br J Dermatol 99 (1978), 469–475.
8. 8 Gelfand, J.M., Troxel, A.B., Lewis, J.D., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143 (2007), 1493–1499.
9. 9 Yeung, H., Takeshita, J., Mehta, N.N., et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 149 (2013), 1173–1179.
10. 10 Tsai, T.F., Wang, T.S., Hung, S.T., et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 63 (2011), 40–46.
11. 11 Gelfand, J.M., Neimann, A.L., Shin, D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006), 1735–1741.
12. 12 Brauchli, Y.B., Jick, S.S., Miret, M., et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 160 (2009), 1048–1056.
13. 13 Wakkee, M., Herings, R.M., Nijsten, T., Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 130 (2010), 962–967.
14. 14 Dowlatshahi, E.A., Kavousi, M., Nijsten, T., et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol 133 (2013), 2347–2354.
15. 15 Parisi, R., Rutter, M.K., Lunt, M., et al. Psoriasis and the risk of major cardiovascular events: cohort study using the Clinical Practice Research Datalink. J Invest Dermatol 135 (2015), 2189–2197.
16. 16 Gelfand, J.M., Azfar, R.S., Mehta, N.N., Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol 130 (2010), 919–922.
17. 17 Gelfand, J.M., Mehta, N.N., Langan, S.M., Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol 131 (2011), 1007–1010.
18. 18 Ogdie, A., Troxel, A.B., Mehta, N.N., et al. Psoriasis and cardiovascular risk: strength in numbers part 3. J Invest Dermatol 135 (2015), 2148–2150.
19. 19 Armstrong, E.J., Harskamp, C.T., Armstrong, A.W., Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc, 2, 2013, e000062.
20. 20 Gaeta, M., Castelvecchio, S., Ricci, C., et al. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. Int J Cardiol 168 (2013), 2282–2288.
21. 21 Gu, W.J., Weng, C.L., Zhao, Y.T., Liu, Q.H., Yin, R.X., Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol 168 (2013), 4992–4996.
22. 22 Horreau, C., Pouplard, C., Brenaut, E., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 27:suppl 3 (2013), 12–29.
23. 23 Miller, I.M., Ellervik, C., Yazdanyar, S., et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 69 (2013), 1014–1024.
24. 24 Pietrzak, A., Bartosinska, J., Chodorowska, G., et al. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 52 (2013), 153–162.
25. 25 Samarasekera, E.J., Neilson, J.M., Warren, R.B., et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 133 (2013), 2340–2346.
26. 26 Xu, T., Zhang, Y.H., Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol 167 (2012), 1345–1350.
27. 27 Armstrong, A.W., Harskamp, C.T., Ledo, L., et al. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 109 (2012), 976–980.
28. 28 Li, W.Q., Han, J.L., Manson, J.E., et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 166 (2012), 811–818.
29. 29 Mehta, N.N., Yu, Y., Pinnelas, R., et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med 124 (2011), 775.e1–775.e6.
30. 30 Ahlehoff, O., Gislason, G.H., Charlot, M., et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 270 (2011), 147–157.
31. 31 Mehta, N.N., Krishnamoorthy, P., Yu, Y., et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol 67 (2012), 796–798.
32. 32 Ogdie, A., Yu, Y., Haynes, K., et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 74 (2015), 326–332.
33. 33 Nestle, F.O., Kaplan, D.H., Barker, J., Psoriasis. N Engl J Med 361 (2009), 496–509.
34. 34 Packard, R.R., Lichtman, A.H., Libby, P., Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 31 (2009), 5–22.
35. 35 Armstrong, A.W., Voyles, S.V., Armstrong, E.J., et al. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 63 (2011), 1–9.
36. 36 Armstrong, A.W., Voyles, S.V., Armstrong, E.J., et al. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 20 (2011), 544–549.
37. 37 Spah, F., Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159:suppl 2 (2008), 10–17.
38. 38 Wang, Y., Gao, H., Loyd, C.M., et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol 132 (2012), 2067–2075.
39. 39 Davidovici, B.B., Sattar, N., Prinz, J., et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130 (2010), 1785–1796.
40. 40 Mehta, N.N., Reilly, M.P., Monocyte mayhem: do subtypes modulate distinct atherosclerosis phenotypes?. Circ Cardiovasc Genet 5 (2012), 7–9.
41. 41 Noels, H., Weber, C., Catching up with important players in atherosclerosis: type I interferons and neutrophils. Curr Opin Lipidol 22 (2011), 144–145.
42. 42 Alexandroff, A.B., Pauriah, M., Camp, R.D., et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 161 (2009), 1–7.
43. 43 Puig, J.G., Mateos, F.A., Jimenez, M.L., et al. Uric acid metabolism in psoriasis. Adv Exp Med Biol 195 Pt A (1986), 411–416.
44. 44 Cassano, N., Carbonara, M., Panaro, M., et al. Role of serum uric acid in conditioning the association of psoriasis with metabolic syndrome. Eur J Dermatol 21 (2011), 808–809.
45. 45 Martínez-Sales, V., Vila, V., Ricart, J.M., et al. Increased circulating endothelial cells and microparticles in patients with psoriasis. Clin Hemorheol Microcirc 60 (2015), 283–290.
46. 46 Pelletier, F., Garnache-Ottou, F., Angelot, F., et al. Increased levels of circulating endothelial-derived microparticles and small-size platelet-derived microparticles in psoriasis. J Invest Dermatol 131 (2011), 1573–1576.
47. 47 Tamagawa-Mineoka, R., Katoh, N., Kishimoto, S., Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J Am Acad Dermatol 62 (2010), 621–626.
48. 48 Takeshita, J., Mohler, E.R., Krishnamoorthy, P., et al. Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. J Am Heart Assoc, 3, 2014, e000507.
49. 49 Rose, S., Stansky, E., Dagur, P.K., et al. Characterization of immune cells in psoriatic adipose tissue. J Transl Med, 12, 2014, 258.
50. 50 Cheung, L., Fisher, R.M., Kuzmina, N., et al. Psoriasis skin inflammation-induced microRNA-26b targets NCEH1 in underlying subcutaneous adipose tissue. J Invest Dermatol 136 (2016), 640–648.
51. 51 Karbach, S., Croxford, A.L., Oelze, M., et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34 (2014), 2658–2668.
52. 52 Mehta, N.N., Yu, Y., Saboury, B., et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol 147 (2011), 1031–1039.
53. 53 Naik, H.B., Natarajan, B., Stansky, E., et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol 35 (2015), 2667–2676.
54. 54 Bowden, D.W., Rudock, M., Ziegler, J., et al. Coincident linkage of type 2 diabetes, metabolic syndrome, and measures of cardiovascular disease in a genome scan of the diabetes heart study. Diabetes 55 (2006), 1985–1995.
55. 55 Parker, A., Meyer, J., Lewitzky, S., et al. A gene conferring susceptibility to type 2 diabetes in conjunction with obesity is located on chromosome 18p11. Diabetes 50 (2001), 675–680.
56. 56 Park, M.H., Kwak, S.H., Kim, K.J., et al. Identification of a genetic locus on chromosome 4q34-35 for type 2 diabetes with overweight. Exp Mol Med, 45, 2013, e7.
57. 57 Ng, M.C., So, W.Y., Lam, V.K., et al. Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 53 (2004), 2676–2683.
58. 58 Ng, M.C., So, W.Y., Cox, N.J., et al. Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes 53 (2004), 1609–1613.
59. 59 Wolf, N., Quaranta, M., Prescott, N.J., et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45 (2008), 114–116.
60. 60 Campalani, E., Allen, M.H., Fairhurst, D., et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 154 (2006), 345–352.
61. 61 Nair, R.P., Ruether, A., Stuart, P.E., et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 128 (2008), 1653–1661.
62. 62 Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2, Strange, A., Capon, F., Spencer, C.C., et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 42 (2010), 985–990.
63. 63 Fung, E.Y., Smyth, D.J., Howson, J.M., et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 10 (2009), 188–191.
64. 64 Suarez-Farinas, M., Li, K., Fuentes-Duculan, J., et al. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132 (2012), 2552–2564.
65. 65 Eiris, N., Gonzalez-Lara, L., Santos-Juanes, J., et al. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus. J Dermatol Sci 75 (2014), 167–172.
66. 66 Mehta, N.N., Li, K., Szapary, P., et al. Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med, 11, 2013, 194.
67. 67 Koch, M., Baurecht, H., Ried, J.S., et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol 135 (2015), 1283–1293.
68. 68 Setty, A.R., Curhan, G., Choi, H.K., Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 (2007), 1670–1675.
69. 69 Kumar, S., Han, J., Li, T., et al. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 27 (2013), 1293–1298.
70. 70 Naldi, L., Chatenoud, L., Linder, D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005), 61–67.
71. 71 Armstrong, A.W., Harskamp, C.T., Armstrong, E.J., The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes, 2, 2012, e54.
72. 72 Langan, S.M., Seminara, N.M., Shin, D.B., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol 132:3 pt 1 (2012), 556–562.
73. 73 Armstrong, A.W., Harskamp, C.T., Armstrong, E.J., The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 31 (2013), 433–442.
74. 74 Qureshi, A.A., Choi, H.K., Setty, A.R., et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 145 (2009), 379–382.
75. 75 Kaye, J.A., Li, L., Jick, S.S., Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159 (2008), 895–902.
76. 76 Armstrong, A.W., Lin, S.W., Chambers, C.J., et al. Psoriasis and hypertension severity: results from a case-control study. PLoS ONE, 6, 2011, e18227.
77. 77 Takeshita, J., Wang, S., Shin, D.B., et al. Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom. JAMA Dermatol 151 (2015), 161–169.
78. 78 Armstrong, A.W., Harskamp, C.T., Armstrong, E.J., Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 149 (2013), 84–91.
79. 79 Azfar, R.S., Seminara, N.M., Shin, D.B., et al. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol 148 (2012), 995–1000.
80. 80 Armstrong, A.W., Guerin, A., Sundaram, M., et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol 72 (2015), 968–977.e2.
81. 81 Ma, C., Harskamp, C.T., Armstrong, E.J., et al. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 168 (2013), 486–495.
82. 82 Wu, S., Li, W.Q., Han, J., et al. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheum 66 (2014), 304–310.
83. 83 Mallbris, L., Granath, F., Hamsten, A., et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54 (2006), 614–621.
84. 84 Mehta, N.N., Li, R., Krishnamoorthy, P., et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 224 (2012), 218–221.
85. 85 Holzer, M., Wolf, P., Curcic, S., et al. Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res 53 (2012), 1618–1624.
86. 86 Tom, W.L., Playford, M.P., Admani, S., et al. Characterization of lipoprotein composition and function in pediatric psoriasis reveals a more atherogenic profile. J Invest Dermatol 136 (2016), 67–73.
87. 87 Salahuddin, T., Natarajan, B., Playford, M.P., et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J 36 (2015), 2662–2665.
88. 88 Kassi, E., Pervanidou, P., Kaltsas, G., et al. Metabolic syndrome: definitions and controversies. BMC Med, 9, 2011, 48.
89. 89 Armstrong, A.W., Harskamp, C.T., Armstrong, E.J., Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 68 (2013), 654–662.
90. 90 Gutmark-Little, I., Shah, K.N., Obesity and the metabolic syndrome in pediatric psoriasis. Clin Dermatol 33 (2015), 305–315.
91. 91 Najarian, D.J., Gottlieb, A.B., Connections between psoriasis and Crohn's disease. J Am Acad Dermatol 48 (2003), 805–821.
92. 92 Skroza, N., Proietti, I., Pampena, R., et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int, 2013, 2013, 983902.
93. 93 Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447 (2007), 661–678.
94. 94 Ellinghaus, D., Ellinghaus, E., Nair, R.P., et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet 90 (2012), 636–647.
95. 95 Cohen, A.D., Dreiher, J., Birkenfeld, S., Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 23 (2009), 561–565.
96. 96 Li, W.Q., Han, J.L., Chan, A.T., et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in U.S. women. Ann Rheum Dis 72 (2013), 1200–1205.
97. 97 Bernstein, C.N., Wajda, A., Blanchard, J.F., The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129 (2005), 827–836.
98. 98 Yates, V.M., Watkinson, G., Kelman, A., Further evidence of an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol 106 (1982), 323–330.
99. 99 Lee, F.I., Bellary, S.V., Francis, C., Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 85 (1990), 962–963.
100. 100 Younossi, Z.M., Stepanova, M., Afendy, M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9 (2011), 524–530.e521.
101. 101 Candia, R., Ruiz, A., Torres-Robles, R., et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 29 (2015), 656–662.
102. 102 Singh, N.P., Prakash, A., Kubba, S., et al. Psoriatic nephropathy–does an entity exist?. Ren Fail 27 (2005), 123–127.
103. 103 Abuabara, K., Azfar, R.S., Shin, D.B., et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 163 (2010), 586–592.
104. 104 Svedbom, A., Dalen, J., Mamolo, C., et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. Acta Derm Venereol 95 (2015), 809–815.
105. 105 Wan, J., Wang, S., Haynes, K., et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. Br J Dermatol, 347, 2013, f5961.
106. 106 Chi, C.C., Wang, J., Chen, Y.F., et al. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci 78 (2015), 232–238.
107. 107 Pouplard, C., Brenaut, E., Horreau, C., et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 27:suppl 3 (2013), 36–46.
108. 108 Chiesa Fuxench, Z.C., Shin, D.B., Ogdie Beatty, A., et al. The risk of cancer in patients with psoriasis: a population-based cohort study in The Health Improvement Network. JAMA Dermatol 152 (2016), 282–290.
109. 109 Brauchli, Y.B., Jick, S.S., Miret, M., et al. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 129 (2009), 2604–2612.
110. 110 Margolis, D., Bilker, W., Hennessy, S., et al. The risk of malignancy associated with psoriasis. Arch Dermatol 137 (2001), 778–783.
111. 111 Gelfand, J.M., Shin, D.B., Neimann, A.L., et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006), 2194–2201.
112. 112 Naldi, L., Peli, L., Parazzini, F., et al. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 44 (2001), 433–438.
113. 113 Telfer, N.R., Chalmers, R.J., Whale, K., et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 128 (1992), 39–42.
114. 114 Patel, R.V., Weinberg, J.M., Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis. Cutis 82 (2008), 117–122.
115. 115 Morar, N., Willis-Owen, S.A., Maurer, T., et al. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 10 (2010), 470–478.
116. 116 Wakkee, M., de Vries, E., van den Haak, P., et al. Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort. J Am Acad Dermatol 65 (2011), 1135–1144.
117. 117 Kao, L.T., Lee, C.Z., Liu, S.P., et al. Psoriasis and the risk of pneumonia: a population-based study. PLoS ONE, 9, 2014, e116077.
118. 118 Takeshita, J., Shin, D.B., Ogdie, A., Gelfand, J.M., Increased risk of serious infection among patients with psoriasis: a population-based cohort study in the United Kingdom. J Invest Dermatol, 136(5 suppl 1), 2016, S34.
119. 119 Takeshita, J., Shin, D.B., Ogdie, A., Gelfand, J.M., Increased risk of pneumonia among patients with psoriasis: a population-based cohort study in the United Kingdom. J Invest Dermatol, 135(5 suppl 1), 2015, S50.
120. 120 Dowlatshahi, E.A., Wakkee, M., Arends, L.R., et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 134 (2014), 1542–1551.
121. 121 Kurd, S.K., Troxel, A.B., Crits-Christoph, P., et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 146 (2010), 891–895.
122. 122 Dommasch, E.D., Li, T., Okereke, O.I., et al. Risk of depression in women with psoriasis: a cohort study. Br J Dermatol 173 (2015), 975–980.
123. 123 Ogdie, A., Weiss, P., The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41 (2015), 545–568.
124. 124 Ogdie, A., Langan, S., Love, T., et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford) 52 (2013), 568–575.
125. 125 Li, R., Sun, J., Ren, L.M., et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford) 51 (2012), 721–729.
126. 126 Yang, Q., Qu, L., Tian, H., et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol 25 (2011), 1409–1414.
127. 127 Carneiro, J.N., Paula, A.P., Martins, G.A., Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasília. An Bras Dermatol 87 (2012), 539–544.
128. 128 Henes, J.C., Ziupa, E., Eisfelder, M., et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatol Int 34 (2014), 227–234.
129. 129 Ibrahim, G., Waxman, R., Helliwell, P.S., The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 61 (2009), 1373–1378.
130. 130 Jamshidi, F., Bouzari, N., Seirafi, H., et al. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med 11 (2008), 162–165.
131. 131 Love, T.J., Gudbjornsson, B., Gudjonsson, J.E., et al. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol 34 (2007), 2082–2088.
132. 132 Haroon, M., Kirby, B., FitzGerald, O., High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 72 (2013), 736–740.
133. 133 Love, T.J., Gudjonsson, J.E., Valdimarsson, H., et al. Psoriatic arthritis and onycholysis – results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol 39 (2012), 1441–1444.
134. 134 Mease, P.J., Gladman, D.D., Papp, K.A., et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69 (2013), 729–735.
135. 135 Khraishi, M., Chouela, E., Bejar, M., et al. High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg 16 (2012), 122–127.
136. 136 Radtke, M.A., Reich, K., Blome, C., et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 23 (2009), 683–691.
137. 137 Reich, K., Kruger, K., Mossner, R., et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective insterdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160 (2009), 1040–1047.
138. 138 Tey, H.L., Ee, H.L., Tan, A.S., et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol 37 (2010), 426–430.
139. 139 Ficco, H.M., Citera, G., Cocco, J.A., Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol 33 (2014), 1489–1493.
140. 140 Wilson, F.C., Icen, M., Crowson, C.S., et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 61 (2009), 233–239.
141. 141 Raposo, I., Torres, T., Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr 106 (2015), 452–457.
142. 142 Merola, J.F., Wu, S., Han, J., et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 74 (2015), 1495–1500.
143. 143 Mody, E., Husni, M.E., Schur, P., et al. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol 157 (2007), 1050–1051.
144. 144 Marchesoni, A., Atzeni, F., Spadaro, A., et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol 39 (2012), 849–855.
145. 145 De Marco, G., Cattaneo, A., Battafarano, N., et al. Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. Arch Dermatol Res 304 (2012), 719–726.
146. 146 Tan, A.L., Grainger, A.J., Tanner, S.F., et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same?. Arthritis Rheum 54 (2006), 1328–1333.
147. 147 Villani, A.P., Rouzaud, M., Sevrain, M., et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol 73 (2015), 242–248.
148. 148 Gladman, D.D., Thavaneswaran, A., Chandran, V., et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. Ann Rheum Dis 70 (2011), 2152–2154.
149. 149 Theander, E., Husmark, T., Alenius, G.M., et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 73 (2014), 407–413.
150. 150 Ogdie, A., Schwartzman, S., Husni, M.E., Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 27 (2015), 118–126.
151. 151 Dreiher, J., Weitzman, D., Shapiro, J., et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 159 (2008), 956–960.
152. 152 Chiang, Y.Y., Lin, H.W., Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. J Eur Acad Dermatol Venereol 26 (2012), 59–65.
153. 153 Yang, Y.W., Keller, J.J., Lin, H.C., Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 165 (2011), 1037–1043.
154. 154 Molina-Leyva, A., Jimenez-Moleon, J.J., Naranjo-Sintes, R., et al. Sexual dysfunction in psoriasis: a systematic review. J Eur Acad Dermatol Venereol 29 (2015), 649–655.
155. 155 Papadavid, E., Vlami, K., Dalamaga, M., et al. Sleep apnea as a comorbidity in obese psoriasis patients: a cross-sectional study. Do psoriasis characteristics and metabolic parameters play a role?. J Eur Acad Dermatol Venereol 27 (2013), 820–826.
156. 156 Yang, Y.W., Kang, J.H., Lin, H.C., Increased risk of psoriasis following obstructive sleep apnea: a longitudinal population-based study. Sleep Med 13 (2012), 285–289.
157. 157 Cohen, J.M., Jackson, C.L., Li, T.Y., et al. Sleep disordered breathing and the risk of psoriasis among US women. Arch Dermatol Res 307 (2015), 433–438.
158. 158 Horn, E.J., Fox, K.M., Patel, V., et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 57 (2007), 957–962.
159. 159 Armstrong, A.W., Robertson, A.D., Wu, J., Schupp, C., Lebwohl, M.G., Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 149 (2013), 1180–1185.